Description

Maytansinoid B is a kind of ADC Cytotoxin. Maytansinoid B can be used to conjugates with antibodies to form antibody-drug conjugates (ADCs). Maytansinoids are known as antimitotic agents, binding to tubulin and inhibiting microtubule assembly. Maytansinoids induces G2/M arrest in the cell cycle to induce apoptosis[1][2].–20°C, 3 years; 4°C, 2 years (Powder)-Applications-Cancer-programmed cell death-Formula-C36H51ClN4O10-Citation–References-[1]Blanc V, et al. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011 Oct 15;17(20):6448-58. |[2]Andreev Julian, et al. Bispecific antigen binding molecules that bind HER2, and methods of use thereof: World Intellectual Property Organization, WO2021174113. 2021-09-02. -CASNumber-1628543-40-7-MolecularWeight-735.26-Compound Purity-99.06-SMILES-O=C(N(C)[C@@H](C)C(O[C@H]([C@@]1(C)[C@@H](O1)[C@@H]2C)CC(N(C)C3=C(Cl)C(OC)=CC(C/C(C)=C/C=C/[C@@H](OC)[C@]4(O)NC(O[C@H]2C4)=O)=C3)=O)=O)CCNC-Research_Area-Cancer-Solubility-DMSO : 100 mg/mL (ultrasonic)-Target-ADC Cytotoxin-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related